Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 Ibero- and native americans: RIBEF-CEIBA Consortium Report on popul...

• Autores: Naranjo, María Eugenia G.; Rodrigues Soares, Fernanda; Peñas Lledó, Eva M.; Tarazona Santos, Eduardo; Fariñas, Humberto; Rodeiro, Idania; Terán, Enrique; Grazina, Manuela; Moya, Graciela E.; López López, Marisol; Sarmiento, Alba P.; Calzadilla, Luis R.; Ramírez Roa, Ronald; Ortiz López, Rocío; Estévez Carrizo, Francisco E.; Sosa Macías, Martha; Barrantes, Ramiro; LLerena, Adrián
• Año de publicación: 2018
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: OMICS: A Journal of Integrative Biology. 2018, 22(09)
• Materia: FARMACOGENETICA; GENOTIPOS; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6
• Institución: Pontificia Universidad Católica Argentina

Fil: Naranjo, María Eugenia G. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Naranjo, María Eugenia G. Universidad de Extremadura; España
Fil: Rodrigues Soares, Fernanda. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Rodrigues Soares, Fernanda. Universidade Federal de Minas Gerais; Brasil
Fil: Rodrigues Soares, Fernanda. Faculdade Uninassau; Brasil
Fil: Peñas Lledó, Eva M. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Peñas Lledó, Eva M. Universidad de Extremadura; España
Fil: Tarazona Santos, Eduardo. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Tarazona Santos, Eduardo. Universidade Federal de Minas Gerais; Brasil
Fil: Tarazona Santos, Eduardo. Prisma; Perú
Fil: Fariñas, Humberto. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Fariñas, Humberto. Universidad de Extremadura; España
Fil: Rodeiro, Idania. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Rodeiro, Idania. Instituto de Ciencias del Mar; Cuba
Fil: Terán, Enrique. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Terán, Enrique. Universidad San Francisco de Quito; Ecuadro
Fil: Grazina, Manuela. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Grazina, Manuela. University of Coimbra; Portugal
Fil: Moya, Graciela E. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Moya, Graciela E. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: López López, Marisol. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: López López, Marisol. Universidad Autónoma Metropolitana; México
Fil: Sarmiento, Alba P. Pontifica Universidad Javeriana; Colombia
Fil: Calzadilla, Luis R. Centro Comunitario de Salud Mental de la Habana Vieja; Cuba
Fil: Calzadilla, Luis R. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Ramírez Roa, Ronald. Universidad Nacional Autónoma de Nicaragua; Nicaragua
Fil: Ramírez Roa, Ronald. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Ortiz López, Rocío. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Ortiz López, Rocío. Tecnológico de Monterrey; México
Fil: Estévez Carrizo, Francisco E. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Estévez Carrizo, Francisco E. Universidad de Montevideo; Uruguay
Fil: Sosa Macías, Martha. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Sosa Macías, Martha. Instituto Politécnico Nacional; México
Fil: Barrantes, Ramiro. Universidad de Costa Rica
Fil: Barrantes, Ramiro. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Llerena Adrián. RIBEF Ibero-American Network of Pharmacogenetics and Pharmacogenomics; España
Fil: Llerena Adrián. Universidad de Extremadura; España
Abstarct Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was established to characterize interindividual and between population variations in CYP2D6, CYP2C9, and CYP2C19 drug metabolizing enzyme genotypes, which were subsequently utilized to catalog their "predicted drug metabolism phenotypes" across Native American and Ibero American populations. Importantly, we report in this study, a total of 6060 healthy individuals from Ibero-America who were classified according to their self-reported ancestry: 1395 Native Americans, 2571 Admixed Latin Americans, 96 Afro-Latin Americans, 287 white Latin Americans (from Cuba), 1537 Iberians, and 174 Argentinean Ashkenazi Jews. Moreover, Native Americans were grouped into North-, Central-, and South Amerindians (from Mexico, Costa Rica, and Peru, respectively). All subjects were studied for the most common and functional CYP2D6, CYP2C9, and CYP2C19 allelic variants, and grouped as genotype-predicted poor or ultrarapid metabolizer phenotypes (gPMs and gUMs, respectively). Native Americans showed differences from each ethnic group in at least two alleles of CYP2D6, CYP2C9, and CYP2C19. Native Americans had higher frequencies of wild-type alleles for all genes, and lower frequency of CYP2D6*41, CYP2C9*2, and CYP2C19*17 (p < 0.05). Native Americans also showed less CYP2C19 gUMs than the rest of the population sample. In addition, differences within Native Americans (mostly North vs. South) were also found. The interethnic differences described supports the need for population-specific personalized and precision medicine programs for Native Americans. To the best of our knowledge, this is the largest study carried out in Native Americans and other Ibero-American populations analyzing CYP2D6, CYP2C9, and CYP2C19 genetic polymorphisms. Population pharmacogenomics is a nascent field of global health and warrants further research and education.